Searched for
TORRENT PHARMA CIPLA DEAL
Oil slide powers India's stock benchmarks to longest weekly winning run 7 monthsIndian stock markets achieved their longest winning streak in seven months, with the Nifty 50 and BSE Sensex closing higher. Falling crude ...- India's CDMO industry set for global shift as pharma diversifies beyond China: Sai Life SciencesIndian contract manufacturers are poised for significant growth as global pharmaceutical giants diversify away from China. Companies like S...
- Stock Radar: Torrent Power stock showing signs of bottoming out after falling 20% from April 2026 highsTorrent Power shares are showing signs of a comeback after a significant dip, with bulls attempting to regain control. Experts suggest a bu...
- Why Meta tapped Kunal Shah; Beauty’s new factory boomHappy Wednesday! Meta just handed WhatsApp’s steering wheel to Cred’s Kunal Shah, betting he can turn India’s favourite chat app into a pay...
- Indian pharma firms gear up to supply key cancer drug to USIndian drugmakers are stepping up to help the US combat a critical shortage of ifosfamide injection, a vital chemotherapy drug. Leading com...
- Honasa Consumer to buy 58% stake in Fluence Pharma at Rs 135-crore enterprise valueMamaearth's parent company, Honasa Consumer, is acquiring a majority stake in nutraceuticals brand Fluence Pharma for ₹135 crore. This stra...
- Honasa Consumer to acquire majority stake in Fluence Pharma at Rs 135-crore valuationHonasa Consumer has secured a majority stake in Mumbai's hair therapy brand Fluence Pharma for Rs 135 crore. This move marks the company's ...
- Honasa Consumer enters nutraceuticals segment; to acquires 58 pc stake in Fluence PharmaHonasa Consumer, parent of Mamaearth, is acquiring a 58% stake in nutraceuticals firm Fluence Pharma for Rs 135 crore, marking its entry in...
- Defence valuations 'obnoxious'; private banks look strong: Sandip Sabharwal's full market playbookInvestor Sandip Sabharwal cautions that while the defence rally is real, many stock prices have outpaced reality. He favors Bharat Electron...
- Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...
- Sensex rises 291 points, Nifty closes above 24,100; Tech Mahindra, Sun Pharma among top gainersIndian stock markets saw a positive start on Monday, with Sensex and Nifty inching up after Friday's dip. Tech Mahindra led the gains, whil...
- Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US...
- Sell or Hold: Citi maintains buy on Cipla; Motilal Oswal recommends buy on RIL post AGMBrokerages remain bullish on Cipla and Reliance Industries, citing strong growth drivers and attractive valuations. Citi highlights regulat...
- Aurobindo Pharma US gets FTC nod for $250 million acquisition of Lannett CompanyAurobindo Pharma's US arm has secured Federal Trade Commission approval for its $250 million acquisition of Lannett Company. This strategic...
- Stocks in news: Sun Pharma, Tech Mahindra, Tata Motors, Voltas, ONGCIndian markets saw a dip on Friday, with IT stocks leading the decline. Analysts suggest profit-taking occurred near the 24,150 mark. Despi...
- Sun Pharma adds Innovcare to its fold in Rs 271.2 crore all-cash transactionIndia's largest drugmaker, Sun Pharma, is set to acquire Mumbai-based Innovcare Lifesciences for approximately $28.7 million in an all-cash...
- Aurobindo Pharma clears key US hurdle in Lannett acquisition, closing expected soonIndian drug giant Aurobindo Pharma is set for a major US expansion. The company has received crucial antitrust clearance from the US Federa...
- US FTC imposes divestment condition on Aurobindo Pharma's $250 mn Lannett acquisitionThe U.S. Federal Trade Commission (FTC) has mandated that Aurobindo Pharma must sell off four specific drug products. This action is a cond...
- Capitalmind Flexi Cap Fund adds Nestle India and 10 others, exits SBI and 14 others in MayCapitalmind Flexi Cap Fund made significant portfolio adjustments in May. The fund welcomed Nestle India and eleven new stocks. It also div...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
Load More
